• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021     National Institute for Health and Care Excellence (NICE) QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography. NICE diagnostics guidance 43
2021     NIHR Health Services and Delivery Research programme The TRECA study: TRials Engagement in Children and Adolescents
2021     Health Technology Wales (HTW) Corneal crosslinking to treat adults and children with keratoconus
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Agency for Healthcare Research and Quality (AHRQ) Treatments and technologies supporting appropriate opioid tapers
2021     Health Technology Wales (HTW) Freestyle Libre flash glucose monitoring for the management of diabetes
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22]
2021     Agency for Healthcare Research and Quality (AHRQ) Treatments, technologies, and models for management of acute and chronic pain in people with a history of substance use disorder
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Breast cancer"]
2021     NIHR Health Technology Assessment programme Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amikacin sulfate (Mycobacterium avium Complex [MAC] lung infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizanlizumab (sickle cell disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme ROCkeTS - Refining Ovarian Cancer Test Accuracy Scores
2021     NIHR Health Technology Assessment programme A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cold plasma in wound therapy (Addendum to Commission E21-03)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Preventing enduring behavioural problems in young children through early psychological intervention: Healthy Start, Happy Start
2021     NIHR Health Technology Assessment programme A multi-centre cluster randomised controlled trial to evaluate the Guide to Action Care Home fall prevention programme in care homes for older people (FinCH)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Investigating the effectiveness and cost effectiveness of using FITNET to treat paediatric CFS/ME in the UK
2021     Norwegian Institute of Public Health (NIPH) Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Crizanlizumab (repeal of the resolution of 20 May 2021)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, gating mutation) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Statin Web-based Investigation of Side Effects Trial (Statin WISE Trial)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fedratinib (myelofibrosis)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021     NIHR Health Technology Assessment programme Prognostic indicators of severe disEAse in women with late preterm pre-eClampsia tO guide deCision-maKing on timing of delivery (PEACOCK study)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of laparoscopic cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults with uncomplicated symptomatic gallstones (C-Gall)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Alpha-1 antitrypsin genotyping
2021     NIHR Health Technology Assessment programme A randomized controlled trial to study the effectiveness of laser ablation versus observation to prevent anal cancer in men with human immunodeficiency virus who have high-grade anal intraepithelial neoplasia
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Streamlining Medicare Benefits Schedule items for positron emission tomography (PET) project
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of pharmacological treatments for alcohol withdrawal and relapse prevention]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Assessment according to §137h Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Coronary lithoplasty for coronary heart disease - Assessment according to §137h Social Code Book V]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Fear of childbirth, depression and anxiety during pregnancy]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Lumasiran (Hyperoxaluria)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selection of interventions for the "second opinion" procedure according to § 27b Social Code Book V - Rapid Report]
2021     NIHR Health Services and Delivery Research programme Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: a 2x2 factorial randomised controlled trial (The GRASP trial)
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (Myelodysplastic Syndrome (MDS))]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme ALternative To prophylactic Antibiotics for the treatment of Recurrent urinary tract infections in women (ALTAR study)
2021     NIHR Public Health Research (PHR) programme The VIP trial: a randomised controlled trial of the clinical and cost effectiveness of a Victim Improvement Package (VIP) for the reduction of chronic symptoms of depression or anxiety in older victims of common crime
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of single-photon emission computed tomography with [ 123I]ioflupane (DaTscan) in the diagnostic process for parkinsonian syndromes]
2021     Malaysian Health Technology Assessment (MaHTAS) Hyperthermic intraperitoneal chemotherapy as an adjuvant therapy for peritoneal surface malignancy (PSM)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sebelipase alfa (lysosomal acid lipase deficiency) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM)
2021     NIHR Public Health Research (PHR) programme Does slip resistant footwear reduce slips among healthcare workers? A randomised controlled trial
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of neonatal pulse oximetry screening for critical congenital heart disease]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; pretreated) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. NICE technology appraisal guidance 668
2021     NIHR Health Technology Assessment programme How do smoking cessation medicines compare with respect to their neuropsychiatric safety: a systematic review, network meta-analysis and cost effectiveness analysis.
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: mammographic density and breast cancer screening]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Artificial intelligence in surgery and surgical education
2021     National Institute for Health and Care Excellence (NICE) Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2021     NIHR Health Technology Assessment programme OPTIMA: Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis
2021     Swiss Federal Office of Public Health (FOPH) Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson’s disease
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Mepolizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 671
2021     NIHR Public Health Research (PHR) programme The impact of a family-based physical activity promotion programme on child physical activity: feasibility and pilot of the Families Reporting Every Step to Health (FRESH) intervention.
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2021     NIHR Health Services and Delivery Research programme Accounting for multimorbidity, competing risk and direct treatment disutility in risk prediction tools and model-based cost-effectiveness analysis for the primary prevention of cardiovascular disease and osteoporotic fracture
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2021     National Authority for Assessment and Accreditation in Healthcare (INEAS) ZELBORAF® (vemurafenib) en monothérapie dans le traitement du mélanome non résécable ou métastatique à mutation BRAF V600
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2021     NIHR Public Health Research (PHR) programme Evaluating graduated progress towards and impacts of the implementation of indoor smoke free prison facilities in Scotland